MedTrace Logo

Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)

NCT01078220 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 189629

Last updated 2017-07-11

Study results available
· View outcomes & findings →

Summary

This is a post-licensure safety surveillance program to detect potential safety signals in subjects, from the managed care organizations database, who have used GARDASIL™.

Conditions

  • Human Papillomavirus Infection

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Eligibility

Min Age
9 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-02-06
Primary Completion
2010-12-13
Completion
2010-12-13

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01078220 on ClinicalTrials.gov